PROVIDENCE – ProThera Biologics Inc. has been awarded a two-year $1.9 million Phase II grant from the National Institutes of Health to study the potential of a new test to assess prognosis of infants who have or might develop sepsis and necrotizing entercolitis, the company announced Wednesday. The Small Business Innovation Research Fast Track grant…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.